Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MBI/Mallinckrodt ultrasound contrast agent patent suit argues perfluorocarbon technology is not patentable.

  • News

Executive Summary

PERFLUOROCARBON TECHNOLOGY IS NOT PATENTABLE, MBI/MALLINCKRODT ASSERT in a lawsuit filed in Washington, D.C. federal court July 31. The suit seeks to invalidate patents covering ultrasound contrast agents using perfluorocarbon gases held by Sonus, Nycomed, ImaRx/DuPont Merck and Bracco. Molecular Biosystems and marketing partner Mallinckrodt seek a declaratory judgment that the defendants' patents "are each invalid and unenforceable, and that the manufacture, use and sale of Optison [FS069] will not infringe any of said patents to the extent the patents are valid and enforceable."

Table

View full table

Tags:
Latest Headlines

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

See All
UsernamePublicRestriction

Register

PS030697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By